Associated Papers
Functional characterization of all CDKN2A missense variants and comparison to in silico models of pathogenicity.
Kimura H et al.
Biorxiv : the Preprint Server for Biology, 2025
38234851 (PubMed )
Supplement: media-2.pdf
Efficacy of BRAF and MEK Inhibition in Patients with BRAF-Mutant Advanced Melanoma and Germline CDKN2A Pathogenic Variants.
Spagnolo F et al.
Cancers, 2021
34069952 (PubMed )
Supplement: cancers-13-02440-s001.zip › cancers-1207401-supplementary.pdf
CDKN2A germline mutations are not associated with poor survival in an Italian cohort of melanoma patients.
Dalmasso B et al.
Journal of the American Academy of Dermatology, 2019
Multiple primary melanomas (MPMs) and criteria for genetic assessment: MultiMEL, a multicenter study of the Italian Melanoma Intergroup.
Bruno W et al.
Journal of the American Academy of Dermatology, 2016
Mutational Status of CDKN2A and TP53 Genes in Laryngeal Squamous Cell Carcinoma.
Todorova TA et al.
Pathology Oncology Research : Por, 2015
Select a paper to view details